Research ExplorerPublicationsRetrospective analysis of long-term lipid apheresis at a sin...

Retrospective analysis of long-term lipid apheresis at a single center

Standard

Retrospective analysis of long-term lipid apheresis at a single center. / Koziolek, Michael J; Hennig, Ulrich; Zapf, Antonia; Bramlage, Carsten; Grupp, Clemens; Armstrong, Victor W; Strutz, Frank; Müller, Gerhard A.

In: THER APHER DIAL, Vol. 14, No. 2, 04.2010, p. 143-152.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Koziolek, MJ, Hennig, U, Zapf, A, Bramlage, C, Grupp, C, Armstrong, VW, Strutz, F & Müller, GA 2010, 'Retrospective analysis of long-term lipid apheresis at a single center', THER APHER DIAL, vol. 14, no. 2, pp. 143-152. https://doi.org/10.1111/j.1744-9987.2009.00747.x

APA

Koziolek, M. J., Hennig, U., Zapf, A., Bramlage, C., Grupp, C., Armstrong, V. W., Strutz, F., & Müller, G. A. (2010). Retrospective analysis of long-term lipid apheresis at a single center. THER APHER DIAL, 14(2), 143-152. https://doi.org/10.1111/j.1744-9987.2009.00747.x

Vancouver

Koziolek MJ, Hennig U, Zapf A, Bramlage C, Grupp C, Armstrong VW et al. Retrospective analysis of long-term lipid apheresis at a single center. THER APHER DIAL. 2010 Apr;14(2):143-152. https://doi.org/10.1111/j.1744-9987.2009.00747.x

Bibtex

@article{2b1e1357e04a4d499e3d1f75ebff19ff,
title = "Retrospective analysis of long-term lipid apheresis at a single center",
abstract = "We retrospectively analyzed 10 906 lipid apheresis sessions (heparin-induced lipoprotein precipitation, direct adsorption of lipoproteins, double filtration plasmapheresis, dextran sulfate adsorption, and immunoadsorption) in 38 patients who were consecutively treated in our department during the last 20 years. The incidences of major cardiovascular events (MACE) (death, cerebrovascular accident, myocardial infarction, limb amputation, and renal vascular involvement) were taken separately as primary end-points or as a combined end-point. The time-course of secondary end-points (coronary and extracranial status of arteries, left ventricular function, occlusive artery disease, and calculated glomerular filtration rate [cGFR]) were also evaluated, as well as the extent of the reduction in plasma lipids and lipoproteins and the incidence of therapy associated side-effects. MACE decreased from 7.02% events per patient per year at the start of lipid apheresis to 1.17% during lipid apheresis and the rate of myocardial revascularization decreased from 22.8% to 3.8% per patient per year. Classical (diabetes mellitus, arterial hypertension, and smoking history), as well as novel risk factors (cGFR < 60 mL/min, statin withdrawal, mixed hyperlipoproteinemia, and elevated lipoprotein (a)) were associated with an elevated risk for MACE. All applied methods had comparable effects. All lipid apheresis methods proved to be safe and suitable for long-term treatment. The present data demonstrate that treatment with lipid apheresis is very effective and leads to long-term reduction in cardiovascular mortality and morbidity.",
keywords = "Adult, Blood Component Removal, Cardiovascular Diseases, Dextran Sulfate, Filtration, Follow-Up Studies, Heparin, Humans, Hyperlipidemias, Immunosorbent Techniques, Lipoproteins, Male, Middle Aged, Plasmapheresis, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Comparative Study, Journal Article",
author = "Koziolek, {Michael J} and Ulrich Hennig and Antonia Zapf and Carsten Bramlage and Clemens Grupp and Armstrong, {Victor W} and Frank Strutz and M{\"u}ller, {Gerhard A}",
year = "2010",
month = apr,
doi = "10.1111/j.1744-9987.2009.00747.x",
language = "English",
volume = "14",
pages = "143--152",
journal = "THER APHER DIAL",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Retrospective analysis of long-term lipid apheresis at a single center

AU - Koziolek, Michael J

AU - Hennig, Ulrich

AU - Zapf, Antonia

AU - Bramlage, Carsten

AU - Grupp, Clemens

AU - Armstrong, Victor W

AU - Strutz, Frank

AU - Müller, Gerhard A

PY - 2010/4

Y1 - 2010/4

N2 - We retrospectively analyzed 10 906 lipid apheresis sessions (heparin-induced lipoprotein precipitation, direct adsorption of lipoproteins, double filtration plasmapheresis, dextran sulfate adsorption, and immunoadsorption) in 38 patients who were consecutively treated in our department during the last 20 years. The incidences of major cardiovascular events (MACE) (death, cerebrovascular accident, myocardial infarction, limb amputation, and renal vascular involvement) were taken separately as primary end-points or as a combined end-point. The time-course of secondary end-points (coronary and extracranial status of arteries, left ventricular function, occlusive artery disease, and calculated glomerular filtration rate [cGFR]) were also evaluated, as well as the extent of the reduction in plasma lipids and lipoproteins and the incidence of therapy associated side-effects. MACE decreased from 7.02% events per patient per year at the start of lipid apheresis to 1.17% during lipid apheresis and the rate of myocardial revascularization decreased from 22.8% to 3.8% per patient per year. Classical (diabetes mellitus, arterial hypertension, and smoking history), as well as novel risk factors (cGFR < 60 mL/min, statin withdrawal, mixed hyperlipoproteinemia, and elevated lipoprotein (a)) were associated with an elevated risk for MACE. All applied methods had comparable effects. All lipid apheresis methods proved to be safe and suitable for long-term treatment. The present data demonstrate that treatment with lipid apheresis is very effective and leads to long-term reduction in cardiovascular mortality and morbidity.

AB - We retrospectively analyzed 10 906 lipid apheresis sessions (heparin-induced lipoprotein precipitation, direct adsorption of lipoproteins, double filtration plasmapheresis, dextran sulfate adsorption, and immunoadsorption) in 38 patients who were consecutively treated in our department during the last 20 years. The incidences of major cardiovascular events (MACE) (death, cerebrovascular accident, myocardial infarction, limb amputation, and renal vascular involvement) were taken separately as primary end-points or as a combined end-point. The time-course of secondary end-points (coronary and extracranial status of arteries, left ventricular function, occlusive artery disease, and calculated glomerular filtration rate [cGFR]) were also evaluated, as well as the extent of the reduction in plasma lipids and lipoproteins and the incidence of therapy associated side-effects. MACE decreased from 7.02% events per patient per year at the start of lipid apheresis to 1.17% during lipid apheresis and the rate of myocardial revascularization decreased from 22.8% to 3.8% per patient per year. Classical (diabetes mellitus, arterial hypertension, and smoking history), as well as novel risk factors (cGFR < 60 mL/min, statin withdrawal, mixed hyperlipoproteinemia, and elevated lipoprotein (a)) were associated with an elevated risk for MACE. All applied methods had comparable effects. All lipid apheresis methods proved to be safe and suitable for long-term treatment. The present data demonstrate that treatment with lipid apheresis is very effective and leads to long-term reduction in cardiovascular mortality and morbidity.

KW - Adult

KW - Blood Component Removal

KW - Cardiovascular Diseases

KW - Dextran Sulfate

KW - Filtration

KW - Follow-Up Studies

KW - Heparin

KW - Humans

KW - Hyperlipidemias

KW - Immunosorbent Techniques

KW - Lipoproteins

KW - Male

KW - Middle Aged

KW - Plasmapheresis

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Comparative Study

KW - Journal Article

U2 - 10.1111/j.1744-9987.2009.00747.x

DO - 10.1111/j.1744-9987.2009.00747.x

M3 - SCORING: Journal article

C2 - 20438535

VL - 14

SP - 143

EP - 152

JO - THER APHER DIAL

JF - THER APHER DIAL

SN - 1744-9979

IS - 2

ER -